| Document |
Document Title |
|
WO/2021/125474A1 |
Edoxaban p-toluenesulfonate monohydrate that is currently on the market has problems of having very poor crystallinity, being unstable due to moisture, being a pale yellow solid in terms of solid color, and being not easy to tablet durin...
|
|
WO/2021/125291A1 |
The present disclosure provides a novel thrombin action inhibitor, a composition for preventing skin disorders caused by pollens, and a cosmetic or non-therapeutic method for preventing skin disorders caused by pollens. More specifically...
|
|
WO/2021/123033A1 |
The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four α-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming α-helices t...
|
|
WO/2021/125345A1 |
Provided is a vasodilator that can dilate a blood vessel even in an environment where ROS are present. This vasodilator includes the compound represented by formula (1) or a salt thereof. In formula (1), ring A and ring B may be the sa...
|
|
WO/2021/120376A1 |
A composite probiotic composition having an anti-aging effect and a preparation method therefor and an application thereof. The composition comprises: 1-10 parts of Bifidobacterium, 1-10 parts of Lactobacillus bulgaricus, 1-10 parts of S...
|
|
WO/2021/115465A1 |
An isolated monoclonal antibody that specifically binds human RANKL, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a me...
|
|
WO/2021/113974A1 |
Multivalent anti-platelet glycoprotein l(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein l(b)alpha and lacking a Fc portion, therefore do not in...
|
|
WO/2021/119040A1 |
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
|
|
WO/2021/119189A1 |
The present invention relates to compositions and methods for identifying at-risk patients and modulating thrombotic conditions in a cancer patient. Embodiments provided herein include a method of determining risk for a thrombotic event ...
|
|
WO/2021/115886A1 |
An isolated recombinant soluble endothelial cell protein C receptor (r-sEPCR) for use as a hemostatic agent.
|
|
WO/2021/108862A1 |
The present invention relates to an anti-FXII antibody for use in a method of treating or preventing hereditary angioedema (HAE) in a subject, wherein the antibody is administered subcutaneously to the subject.
|
|
WO/2021/110127A1 |
A method for treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hemoglobin to the subject.
|
|
WO/2021/113696A1 |
The present application provides for a method for controlling coagulation in a subject in need of extracorporeal membrane oxygenation. The method comprises administering an effective amount of an anticoagulant agent that directly inhibit...
|
|
WO/2021/113682A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/110959A1 |
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of...
|
|
WO/2021/113765A1 |
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enh...
|
|
WO/2021/109979A1 |
Provided are compositions comprising: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one...
|
|
WO/2021/110076A1 |
The present invention belongs to the field of medicinal chemistry and relates to oxamide derivatives, a preparation method therefor and the use thereof in medicine. In particular, provided is a compound of formula (I) or a stereoisomer, ...
|
|
WO/2021/113800A1 |
Factor VIII variants and methods of use thereof are disclosed. In accordance with the present invention, compositions and methods for the modulation of hemostasis in patients in need thereof are provided. More specifically. Factor VIII (...
|
|
WO/2021/110942A1 |
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising maltose and isomalt as diluents. The invention further relates to the us...
|
|
WO/2021/112597A1 |
The present invention relates to a pharmaceutical composition for treating diabetic retinopathy. According to the present invention, the pharmaceutical composition can treat diabetic retinopathy by means of a single administration and th...
|
|
WO/2021/112207A1 |
The present invention provides a means for treating a symptom of cerebral infarction in a cerebral infarction patient, particularly in an acute stage cerebral infarction patient, without causing undesirable side effects, by optimizing th...
|
|
WO/2021/113686A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/104353A1 |
The present invention relates to a crystal form of a quinolinone compound and a use thereof. The present invention further relates to a pharmaceutical composition comprising the crystal form, and a use of the crystal form or the pharmace...
|
|
WO/2021/107125A1 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on LPA3. As a result of having performed thoroughgoing studies, the inventors perfected the p...
|
|
WO/2021/104427A1 |
A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition comprising the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the prepara...
|
|
WO/2021/106988A1 |
It was found that a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has potent G9a inhibitory activity. Because of the ability to inhibit G9a, the compound (I) or a pharmaceutically acceptable sa...
|
|
WO/2021/107117A1 |
A method for producing a hematopoietic cell from a pluripotent stem cell, the method including a first step for culturing naïve pluripotent stem cells and inducing differentiation into yolk sac cells, a second step for culturing primed ...
|
|
WO/2021/105389A1 |
Antibodies to the enzyme matriptase‐2 (MTP‐2) are presented. Inhibiting MTP‐2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine pr...
|
|
WO/2021/107835A1 |
The present invention provides an oral pharmaceutical composition comprising iron succinate for use in treating iron deficiency in a subject diagnosed with heart failure (HF) with reduced ejection fraction (HFrEF), and a method for treat...
|
|
WO/2021/108806A1 |
Compositions, containers and kits for low temperature storage of a specified quantity of packed red blood cells (RBCs) include L-camitine, HES and blood plasma proteins. Methods of storing a packed RBC blood product, transfusing a packed...
|
|
WO/2021/105137A1 |
Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolys...
|
|
WO/2021/098826A1 |
Use of albiflorin, paeoniflorin or a composition containing albiflorin or paeoniflorin in the preparation of drugs, healthcare products, food nutritional agents or food additives for increasing endogenous erythropoietin; and use of albif...
|
|
WO/2021/098817A1 |
Provided are a dioxopiperazine derivative, a preparation method therefor and pharmaceutical use thereof. In particular, provided are compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2021/101910A1 |
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients also having severe hepatic impairment. Also provided herein are methods for administering voxelotor and avoiding or lessening adverse dru...
|
|
WO/2021/098701A1 |
The present invention relates to the field of food and drugs, specifically to a use of a Malus niedzwetskyana product for inhibiting blood clot formation. The Malus niedzwetskyana product comprises a drug, a regular food product or a hea...
|
|
WO/2021/102326A1 |
This disclosure relates to treatments for reducing the side effects associated with treatment of a medication or drug, such as a chemotherapy medication, being experienced by a patient. This may be accomplished by administering to a pati...
|
|
WO/2021/098692A1 |
An application of a cherry plum product in inhibiting thrombosi. The cherry plum product comprises: jam, dried fruit, fruit preserves, fruit juice, fruit powder, fruit wine, candy, pastry, oral liquid, and fresh cherry plum fruit. The ch...
|
|
WO/2021/099616A1 |
The present invention relates to a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sic...
|
|
WO/2021/101278A1 |
The present invention provides: a functional microscaffold that can be magnetically actuated for effective targeted-treatment of intractable diseases; and a manufacturing method therefor. A functional microscaffold that can be magnetical...
|
|
WO/2021/102258A1 |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
|
|
WO/2021/100031A1 |
Provided is a drug used for the treatment or prevention of cerebral hemorrhage, the drug containing, as active ingredients: the compound of formula (I) or a medically acceptable salt thereof; and an ester or a solvate. 74
|
|
WO/2021/094208A1 |
The invention relates to substituted imidazo pyrimidine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular di...
|
|
WO/2021/095775A1 |
[Problem] The purpose of the present invention is to provide a plant-derived component useful as an antiplasmin agent. [Solution] An antiplasmin agent including an extract of a plant of the family Labiatae, genus Scutellaria; family Zing...
|
|
WO/2021/094209A1 |
The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in p...
|
|
WO/2021/097305A1 |
Compositions, systems and methods for delivering CRISPR/Cas9-based genome editing system and a donor protein to a cell.
|
|
WO/2021/097157A1 |
Provided herein are compositions and methods for treating a Cl esterase inhibitor deficiency by normalizing levels of the Cl esterase inhibitor protein in a subject having HAE.
|
|
WO/2021/097350A1 |
The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBA1 or HBA2 locus in the HSPCs with a transgene encoding a therapeutic pr...
|
|
WO/2021/095945A1 |
The present invention relates to a use of a pharmaceutical composition for treating stroke or sequelae following stroke, the composition comprising a phosphodiesterase type 5 activity inhibitor and a Rho-associasted kinase (ROCK) inhibit...
|
|
WO/2021/095980A1 |
A Sikchijeho-tang composition of the present invention exhibits a blood circulation-enhancing effect as high as or higher than that of Gagamjeho-tang comprising a smoky Prunus mume fruit, a Amomum villosum LOUR. fruit, an Amomum tsao-ko ...
|
